

FORM D

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM D

NOTICE OF SALE OF SECURITIES PURSUANT TO REGULATION D, **SECTION 4(6), AND/OR** UNIFORM LIMITED OFFERING EXEMPTION

14	٥	١	9	1	4
----	---	---	---	---	---

Serial

OMB NUMBER:	3235-0076	
Expires:	April 30, 2008	
Estimated average burden	-	
hours per response	16.00	

SEC USE ONLY

Prefix

5.v 614.1 21.v		DATE RECEIVED
Name of Offering (check if this is an amendment a	nd name has changed, and indicate change.)	
Series B Convertible Preferred Stock		SEC
Filing Under (Check box(es) that apply): Type of Filing: ■ New Filing □ Amendment	Rule 504 □ Rule 505 ■ Rule 506 □ Section	4(6) □ ULOE Mail Processing Section
	A. BASIC IDENTIFICATION DATA	A JAM 2.2 Young
1. Enter the information requested about the issuer		
Name of Issuer (check if this is an amendment and Tempo Pharmaceuticals, Inc.	name has changed, and indicate change.)	Washington, DC 101
Address of Executive Offices (Number and Street	eet, City, State, Zip Code)	Telephone Number (Including Area Code)
161 First Street, Cambridge, MA 02142		617-551-9600
Address of Principal Business Operations (if different from Executive Offices)	(Number and Street, City, State, Zip Code)	Telephone Number (Including Area Code)
Brief Description of Business:		
Drug discovery company		PROCESSED
Type of Business Organization		
■ corporation	☐ limited partnership, already formed	other (please specify): JAN 2 8 2008
□ business trust	☐ limited partnership, to be formed	
Actual or Estimated Date of Incorporation or Organiz Jurisdiction of Incorporation or Organization: (Enter		Estimated I HOMSON FINANCIAL

GENERAL INSTRUCTIONS

Federal:

Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D or Section 4(6), 17 CFR 230.501 et seq. or 15 USC 77d(6).

CN for Canada; FN for other foreign jurisdiction)

When To File: A notice must be filed no later than 15 days after the first sale of securities in the offering. A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date it was mailed by United States registered or certified mail to that address.

When to File: U.S. Securities and Exchange Commission, 100 F Street, N.E., Washington, D.C. 20549.

Copies Required: Five (5) copies of this notice must be filed with the SEC, one of which must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

Information Required: A new filing must contain all information requested. Amendments need only report the name of the issuer and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed with the SEC.

Filing Fee: There is no federal filing fee.

State: This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form. Issuers relying on ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires a payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix to the notice constitutes a part of this notice and must be completed.

ATTENTION

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not result in a loss of an available state exemption unless such exemption is predicated on the filing of a federal notice.

		A. BASIC IDENT	IFICATION DATA		
2. Enter the information requested for the					
 Each promoter of the issuer, if the Each beneficial owner having the 				% or more of a cl	ass of equity securities of the issuer;
 Each executive officer and direct 	or of corporate	issuers and of corporate			
Each general and managing partn		<u> </u>			
	□ Promoter	■ Beneficial Owner	■ Executive Officer	■ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Crane, Alan L.					
Business or Residence Address ((Number and S	treet, City, State, Zip Co	ode)		
c/o Tempo Pharmaceuticals, Inc., 161 Firs	st Street, Cam	bridge, MA 02142		_	
	□ Promoter	■ Beneficial Owner	☐ Executive Officer	☐ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Sengupta, Shiladitya					
	Number and S	treet, City, State, Zip Co	ode)		
c/o Tempo Pharmaceuticals, Inc., 161 Firs	st Street Cam	bridge MA 02142			
	□ Promoter	■ Beneficial Owner	☐ Executive Officer	■ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Sasisekharan, Ram					
	Number and St	reet, City, State, Zip Co	de)		
·			,		
c/o Tempo Pharmaceuticals, Inc., 161 First Check Box(es) that Apply:					
Full Name (Last name first, if individual)	□ Promoter	☐ Beneficial Owner	□Executive Officer	■ Director	☐ General and/or Managing Partner
Tan Pana (223, mano man, manada)					
Roberts, Bryan E. Business or Residence Address (1)	Number and Co	reet, City, State, Zip Co	4-5		
Dusiness of Residence Address (1	Milliner and 21	reet, City, State, Zip Co	ue)		
c/o Tempo Pharmaceuticals, Inc., 161 Firs	st Street, Cam	bridge, MA 02142			
	☐ Promoter	☐ Beneficial Owner	□ Executive Officer	■ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Langer, Robert S.					
Business or Residence Address (Number and S	treet, City, State, Zip Co	ode)		
c/o Tempo Pharmaceuticals, Inc., 161 Firs	st Street, Cam	bridge, MA 02142			
	□ Promoter	☐ Beneficial Owner	☐ Executive Officer	■ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
McGuire, Terry					
	Number and S	treet, City, State, Zip Co	ode)		
c/o Tempo Pharmaceuticals, Inc., 161 Firs	rt Street Com	hridae MA 02142			
Charle Day (and the second	□ Promoter	☐ Beneficial Owner	☐ Executive Officer	■ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Tannan Dahart					
Tepper, Robert Business or Residence Address	(Number and S	Street, City, State, Zip Co	ode)		
Check Boy(es) that Apply			- D		
Check Box(es) that Apply: Full Name (Last name first, if individual)	□ Promoter	☐ Beneficial Owner	■ Executive Officer	□ Director	☐ General and/or Managing Partner
· ··· ··········· (Labe taune titot, it individual)					
Glucksmann, Alexandra	OL -1	O'r O'r O'r O'r	- 1-1		
Business or Residence Address	(Number and)	Street, City, State, Zip Co	ode)		
c/o Tempo Pharmaceuticals, Inc., 161 Firs	st Street, Cam	bridge, MA 02142			

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

		A. BASIC IDENT	IFICATION DATA		
 Enter the information requested for the following: Each promoter of the issuer, if the issuer has been organized within the past five years; Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer; Each executive officer and director of corporate issuers and of corporate general and managing partners of partnership issuers; and Each general and managing partner of partnership issuers. 					
Check Box(es) that Apply:	☐ Promoter	■ Beneficial Owner	☐ Executive Officer	☐ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)		<u></u>			
Polaris Venture Partners IV, L.P. Business or Residence Address	(Niverban and C	treet, City, State, Zip Co	427		
business of Residence Address	(Number and 5	treet, City, State, Zip Co	ue)		
1000 Winter Street, Suite 3350, Walthan	n, MA 02454				
Check Box(es) that Apply:	☐ Promoter	■ Beneficial Owner	☐ Executive Officer	□ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
The Crane Family Irrevocable Trust 20 Business or Residence Address		tenet City State 7in Co.	4-)		
Business of Residence Address	(Number and S	treet, City, State, Zip Co	ue)		
c/o Tempo Pharmaceuticals, Inc., 161 Fi	irst Street, Cam	bridge, MA 02142			
Check Box(es) that Apply:	□ Promoter	■ Beneficial Owner	D Executive Officer	□ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Man or h. A					
Venrock Associates V, L.P. Business or Residence Address	(Number and St	reet, City, State, Zip Cod	la)		
Dusiness of Residence Address	(14millori and 3i	ricer, City, State, Zip Coo	ic <i>)</i>		
30 Venrock Plaza, Room 5508, New Yor	k, NY 10112				
Check Box(es) that Apply:	☐ Promoter	■ Beneficial Owner	□Executive Officer	□ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Lux Ventures II, L.P.					
Business or Residence Address	(Number and St	reet, City, State, Zip Cod	le)		
c/o Lux Capital Management, 140 East	45th Street, 30th	Floor, New York, NY 1	0017		
Check Box(es) that Apply:	☐ Promoter	■ Beneficial Owner	☐ Executive Officer	☐ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Bessemer Venture Partners VII L.P.					
Business or Residence Address	(Number and S	treet, City, State, Zip Coo	de)		····
	•		•		
c/o Bessemer Venture Partners, 1865 Pa					
Check Box(es) that Apply:	☐ Promoter	☐ Beneficial Owner	☐ Executive Officer	□ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Business or Residence Address	(Number and S	treet, City, State, Zip Co.	de)		
Check Box(es) that Apply:					
	□ Promoter	☐ Beneficial Owner	☐ Executive Officer	□ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Business or Residence Address	(Number and	Street, City, State, Zip Co	ode)		
Check Box(es) that Apply:		- D	- F .:		
· · · · · · · · · · · · · · · · · · ·	□ Promoter	☐ Beneficial Owner	☐ Executive Officer	□ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Business or Residence Address	(Number and	Street, City, State, Zip Co	ode)		

B. INFORMATION ABOUT OFFERING						
	Dead in the dead in the first term of the first	Yes	No			
1.	Has the issuer sold, or does the issuer intend to sell, to non-accredited investors in this offering? Answer also in Appendix, Column 2, if filling under ULOE.					
2.	S N/A					
	What is the minimum investment that will be accepted from any individual?	Yes	No			
3.	Does the offering permit joint ownership of a single unit?		0			
4.						
Full :	Name (Last name first, if individual)					
Busin	ness or Residence Address (Number and Street, City, State, Zip Code)					
Nam	e of Associated Broker or Dealer					
State	s in which Person Listed Has Solicited or Intends to Solicit Purchasers (Check "All States" or check individual States)	All States				
_ [A _ [1] _ [1]	IL] _ [IN] _ [IA] _ [KS] _ [KY} _ [LA] _ [ME] _ [MD] _ [MA] _ [MI] _ [MN] MT] _ [NE] _ [NV] _ [NH] _ [NJ] _ [NM] _ [NY] _ [NC] _ [ND] _ [OH] _ [OK]	_ [HI] _ [MS] _ [OR] _ [WY]	_ [ID} _ [MO] _ [PA] _ [PR]			
Full	name (Last name first, if individual)					
Busi	ness or Residence Address (Number and Street, City, State, Zip Code)					
Nam	e of Associated Broker or Dealer					
State	s in which Person Listed Has Solicited or Intends to Solicit Purchasers					
	(Check "All States" or check individual States)	All States				
^]_ [] [] []	IL] _[IN] _[IA] _[KS] _[KY] _[LA] _[ME] _[MD] _[MA] _[MI] _[MN] MT] _[NE] _[NV] _[NH] _[NJ] _[NM] _[NY] _[NC] _[ND] _[OH] _[OK]	_ [HI] _ [MS] _ [OR] _ [WY]	_ [ID] _ [MO] _ [PA] _ [PR]			
Full	Name (Last name first, if individual)					
Busi	ness or Residence Address (Number and Street, City, State, Zip Code)					
Nam	e of Associated Broker or Dealer					
State	s in which Person Listed Has Solicited or Intends to Solicit Purchasers					
	All States					
-[/ [] - [] - []	(L)	_ [HI] _ [MS] _ [OR] _ [WY]	_ [ID] _ [MO] _ [PA] _ [PR]			

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS

1.	Enter the aggregate offering price of securities included in this offering and the total amount already sold. Enter "0" if answer is "none" or "zero." If the transaction is an exchange offering, check this box and indicate in the columns below the amounts of the securities offered for exchange and already exchanged.	Aggregate Offering Price	Amount Already Sold
	Type of Security		
	Debt	\$	\$
	Equity	\$8,125,000	\$ 8,125,000
	□ Common ■ Preferred		
	Convertible Securities (including warrants)	5	s
	Partnership Interests	s	s
	Other (Specify)	s	s
	Total	\$ 8,125,000	\$ 8,125,000
	Answer also in Appendix, Column 3, if filing under ULOE.		
2.	Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero."	Number of Investors	Aggregate Dollar Amount of Purchases
	Accredited Investors		\$ 8,125,000
	Non-accredited Investors		\$
	Total (for filings under Rule 504 only)		s
	Answer also in Appendix, Column 4, if filing under ULOE		<u> </u>
3.	If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C – Question 1. Type of offering	Type of Security	Dollar Amount Sold
	Rule 505		\$
	Regulation A		\$
	Rule 504	, , , , , , , , , , , , , , , , , , , ,	\$
	Total		s
4.	a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate.		
	Transfer Agent's Fees		s
	Printing and Engraving Costs	О	s
	Legal Fees	<u> </u>	\$ 30,000
	Accounting Fees	_	5
	Engineering Fees	0	\$
	Sales Commissions (specify finders' fees separately)		s _
		а	•
	Other Expenses (identify)		3
	Total	•	\$ <u>30,000</u>

 b. Enter the difference between the aggregate offering price given in response to Part C. 1 and total expenses furnished in response to Part C.—Question 4.a. This difference is the "adjusted gross proceeds to the issuer.". 	c		s ,	8.095.000
Indicate below the amount of the adjusted gross proceeds to the issuer used or proposed for each of the purposes shown. If the amount for any purpose is not known, firmish an and check the box to the left of the estimate. The total of the payments listed must equal adjusted gross proceeds to the issuer set forth in response to Part C – Question 4.b above	estimate the	·		
		Payments to Officers, Directors, & Affiliates		Payments To Others
Salaries and fees		s	۵	\$
Purchase of real estate	٥	\$		\$
Purchase, rental or leasing and installation of machinery and equipment	ם	· 5	8	\$
Construction or leasing of plant buildings and facilities	0	\$	a	s
Acquisition of other business (including the value of securities involved in this offering that may be used in exchange for the assets or securities of another issuer pursuant to a	•		a.	
margar)	0	\$		\$
Repayment of indebtedness.	٥	\$	0	\$
Working capital	D	2	•	\$ <u>8.095,000</u>
Other (specify):	_ 0	S	0	\$
	- . o	\$	۵	s
Column Totals		\$0	•	\$_8,095,000
Total Payments Listed (column totals added)	•	■ \$ <u>8</u>	.095,000	_
D. FEDERAL SIGNAT	URE			

Issuer (Print or Type) Tempo Pharmaceuticals, Inc.	Signature M. Z.	Date December 17, 2007
Name of Signer (Print or Type) Alan L. Crane	Title of Signer (Print or Type) Chief Executive Officer	

ATTENTION

Intentional misstatements or omissions of fact constitute federal criminal violations. (See 18 U.S.C. 1001.)

